+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacogenomics Market - Global Forecast 2026-2032- Product Image
Pharmacogenomics Market - Global Forecast 2026-2032- Product Image
New

Pharmacogenomics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5716074
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Pharmacogenomics connects innovations in genomics and therapeutics with clinical practice, enabling more tailored prescribing and supporting healthcare efficiency. This market report provides an actionable overview for senior executives evaluating investment, procurement, or strategic alignment within the evolving pharmacogenomics ecosystem.

Market Snapshot: Pharmacogenomics Market Growth and Trajectory

The Pharmacogenomics Market is experiencing robust expansion, with revenues projected to rise from USD 4.98 billion in 2025 to USD 5.47 billion in 2026, and an expected CAGR of 10.85% through 2032, ultimately reaching USD 10.24 billion. Growth is driven by the shift from specialized research to mainstream clinical integration, with broad relevance for diagnostics, therapeutics, and healthcare policy.

Scope & Segmentation

  • Therapeutic Areas: Cardiology, infectious diseases, neurology, and oncology each drive distinct pharmacogenomics use cases, shaping demand for genetic-guided prescribing, test design, and reporting needs.
  • Product Categories: Consumables such as kits and reagents, specialized clinical and research services, as well as software platforms for data analysis and clinical interpretation, comprise the core product ecosystem.
  • Technology Modalities: Microarrays (expression/SNP), polymerase chain reaction (digital and real-time PCR), and sequencing (next-generation, Sanger) are central to pharmacogenomics testing and biomarker analysis.
  • End Users: Hospital-based and reference diagnostic laboratories, hospitals, pharmaceutical manufacturers, and research organizations present varied workflow and reporting standards.
  • Test Types & Biomarkers: Genotyping and phenotyping tests, with emphasis on germline and somatic biomarker classes, address specific clinical questions and operational requirements.
  • Regional Dynamics: The Americas rely on strong payer engagement and diverse laboratory models, Europe/Middle East/Africa adapt to varying regulations and reimbursement, while Asia-Pacific advances with rapid technology adoption and investment in clinical infrastructure.

Key Takeaways

  • Widespread adoption is enabled by advances in sequencing, automation, and data analysis platforms, reducing manual workload and supporting rapid clinical integration.
  • Integration challenges persist, particularly around diagnostic platform interoperability, software reporting, and biomarker classification, requiring close alignment across clinical stakeholders.
  • Payer expectations are evolving, with increasing emphasis on the value of genetic-guided prescribing, leading to changing procurement and reimbursement strategies across regions.
  • Successful implementation depends on robust clinical services, standardized evidence, and clinician-centric education to translate raw genetic data into actionable therapeutic guidance.
  • Vendor competition and technological modularity allow laboratories and healthcare providers to optimize cost, scalability, and service delivery, fostering resilient operations in the face of supply-chain and regulatory volatility.
  • Regional infrastructure, clinical guidelines, and reimbursement frameworks strongly influence technology adoption patterns and commercial traction for pharmacogenomics solutions.

Tariff Impact on Market Dynamics

Recent changes in US tariff policies are reshaping global supply chain strategies. Increased duties on laboratory instruments and consumables raise operational costs, prompting laboratories and purchasers to diversify suppliers, pursue inventory adjustments, and consider local sourcing. Tariff-driven cost pressures are influencing procurement cycles and encouraging decentralized, modular testing models that prioritize rapid, on-site clinical results. These evolving trade environments also introduce new variables in contract negotiation and investment, urging stakeholders to evaluate long-term total cost of ownership and operational resilience.

Methodology & Data Sources

The report utilizes a mixed-methods approach, combining stakeholder interviews, laboratory workflow assessments, and comparative technology analysis. Primary insights from clinicians, laboratory leaders, and regulatory experts are integrated with peer-reviewed research and technical documentation to ensure comprehensive, actionable findings. Technology and policy trends are further validated through expert panels and workshops, aligning technical data with real-world clinical and commercial requirements.

Why This Report Matters

  • Supports informed capital allocation, procurement planning, and partnership development by providing clear segmentation and strategic guidance.
  • Details operational and regulatory considerations necessary for successful technology integration across diverse healthcare environments.
  • Assists in modeling supply-chain, policy, and vendor risk, especially given tariff shifts and regional market differences.

Conclusion

Pharmacogenomics is moving from specialized research toward everyday clinical utility. Stakeholders equipped with deep segmentation insights, operational strategies, and regional context can capitalize on ongoing market transitions to deliver more precise, effective patient care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Pharmacogenomics Market, by Therapeutic Area
8.1. Cardiology
8.2. Infectious Diseases
8.3. Neurology
8.4. Oncology
9. Pharmacogenomics Market, by Product
9.1. Consumables
9.1.1. Kits
9.1.2. Reagents
9.2. Services
9.2.1. Clinical Services
9.2.2. Research Services
9.3. Software And Platforms
9.3.1. Data Analysis
9.3.2. E-Clinical Solutions
9.3.3. Reporting And Interpretation
10. Pharmacogenomics Market, by Technology
10.1. Microarray
10.1.1. Expression Arrays
10.1.2. SNP Arrays
10.2. Polymerase Chain Reaction
10.2.1. Digital PCR
10.2.2. Real-Time PCR
10.3. Sequencing
10.3.1. Next-Generation Sequencing
10.3.2. Sanger Sequencing
11. Pharmacogenomics Market, by Test Type
11.1. Genotyping
11.2. Phenotyping
12. Pharmacogenomics Market, by Biomarker Type
12.1. Germline
12.2. Somatic
13. Pharmacogenomics Market, by End User
13.1. Diagnostic Laboratories
13.1.1. Hospital-Based Laboratories
13.1.2. Reference Laboratories
13.2. Hospitals
13.3. Pharmaceutical Companies
13.4. Research Organizations
14. Pharmacogenomics Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Pharmacogenomics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Pharmacogenomics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Pharmacogenomics Market
18. China Pharmacogenomics Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. 23andMe, Inc.
19.6. Abbott Laboratories
19.7. Admera Health, Inc.
19.8. Agilent Technologies, Inc.
19.9. Biogen Inc.
19.10. Centogene N.V.
19.11. Color Health, Inc.
19.12. F. Hoffmann-La Roche Ltd.
19.13. Genomic Health, Inc.
19.14. Genomind, Inc.
19.15. Illumina, Inc.
19.16. Invitae Corporation
19.17. Laboratory Corporation of America Holdings
19.18. Myriad Genetics, Inc.
19.19. OneOme, LLC
19.20. Pathway Genomics Corporation
19.21. Qiagen N.V.
19.22. Quest Diagnostics Incorporated
19.23. SOPHiA GENETICS SA
19.24. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES PHARMACOGENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA PHARMACOGENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH SERVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH SERVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY E-CLINICAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY E-CLINICAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY E-CLINICAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REPORTING AND INTERPRETATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REPORTING AND INTERPRETATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REPORTING AND INTERPRETATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY EXPRESSION ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY EXPRESSION ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SNP ARRAYS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SNP ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SNP ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHENOTYPING, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GERMLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GERMLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GERMLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOMATIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOMATIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 171. EUROPE PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. EUROPE PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 173. EUROPE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 174. EUROPE PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 175. EUROPE PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 176. EUROPE PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 177. EUROPE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 178. EUROPE PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 179. EUROPE PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 180. EUROPE PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 181. EUROPE PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 182. EUROPE PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 183. EUROPE PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 184. EUROPE PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 199. AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 200. AFRICA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 201. AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 202. AFRICA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 203. AFRICA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 204. AFRICA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 205. AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 206. AFRICA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 207. AFRICA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 208. AFRICA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 209. AFRICA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 210. AFRICA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 211. AFRICA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. AFRICA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 215. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 216. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 218. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 221. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 222. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 227. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 228. ASEAN PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. ASEAN PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 230. ASEAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 231. ASEAN PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 232. ASEAN PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 233. ASEAN PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 234. ASEAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 235. ASEAN PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 236. ASEAN PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 237. ASEAN PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 238. ASEAN PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 239. ASEAN PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 240. ASEAN PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. ASEAN PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 242. GCC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 243. GCC PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 244. GCC PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 245. GCC PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 246. GCC PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 247. GCC PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 248. GCC PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 249. GCC PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 250. GCC PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 251. GCC PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 252. GCC PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 253. GCC PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 254. GCC PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. GCC PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 270. BRICS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 271. BRICS PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 272. BRICS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 273. BRICS PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 274. BRICS PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 275. BRICS PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 276. BRICS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 277. BRICS PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 278. BRICS PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 279. BRICS PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 280. BRICS PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 281. BRICS PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 282. BRICS PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 283. BRICS PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 284. G7 PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 285. G7 PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 286. G7 PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 287. G7 PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 288. G7 PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 289. G7 PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 290. G7 PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 291. G7 PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 292. G7 PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 293. G7 PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 294. G7 PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 295. G7 PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 296. G7 PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 297. G7 PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 298. NATO PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 299. NATO PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 300. NATO PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 301. NATO PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 302. NATO PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 303. NATO PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 304. NATO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 305. NATO PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 306. NATO PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 307. NATO PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 308. NATO PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 309. NATO PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 310. NATO PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 311. NATO PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 312. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 313. UNITED STATES PHARMACOGENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 314. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 315. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 316. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 317. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 318. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 319. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 320. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 321. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 322. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 323. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 324. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 325. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 326. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 327. CHINA PHARMACOGENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 328. CHINA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 329. CHINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 330. CHINA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 331. CHINA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 332. CHINA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2032 (USD MILLION)
TABLE 333. CHINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 334. CHINA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
TABLE 335. CHINA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 336. CHINA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
TABLE 337. CHINA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 338. CHINA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 339. CHINA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 340. CHINA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Pharmacogenomics market report include:
  • 23andMe, Inc.
  • Abbott Laboratories
  • Admera Health, Inc.
  • Agilent Technologies, Inc.
  • Biogen Inc.
  • Centogene N.V.
  • Color Health, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genomic Health, Inc.
  • Genomind, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • OneOme, LLC
  • Pathway Genomics Corporation
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • SOPHiA GENETICS SA
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.47 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.24 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Pharmacogenomics Services Market - Global Forecast to 2030 - Product Image

Pharmacogenomics Services Market - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Pharmacogenomics Market Report by Technology, Application, End User, and Region 2025-2033 - Product Image

Pharmacogenomics Market Report by Technology, Application, End User, and Region 2025-2033

  • Report
  • 142 Pages
  • Global
From
Molecular Diagnostics in Pharmacogenomics Market Size, Share & Trends Analysis Report by Product (Kits & Assays, Reagents, Services), by Therapeutic Area, by Technology, by Region, and Segment Forecasts, 2025-2033 - Product Image

Molecular Diagnostics in Pharmacogenomics Market Size, Share & Trends Analysis Report by Product (Kits & Assays, Reagents, Services), by Therapeutic Area, by Technology, by Region, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Pharmacogenomics Technology Market Size, Share & Trends Analysis Report by Therapeutic Area (Neurological Disorders, Cardiovascular Disease), Technology (PCR, in-situ Hybridization), Region, with Growth Forecasts, 2025-2030 - Product Image

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report by Therapeutic Area (Neurological Disorders, Cardiovascular Disease), Technology (PCR, in-situ Hybridization), Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Pharmacogenomics Market Report 2025 - Product Image

Pharmacogenomics Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Pharmacogenomics Market

Pharmacogenomics is a field of genomics that studies the relationship between an individual's genetic makeup and their response to drugs. It is used to develop personalized medicine, which is tailored to an individual's genetic profile. This field of genomics has the potential to revolutionize the way drugs are developed and prescribed, as it can help to identify which drugs are most effective for a particular patient. It can also help to reduce the risk of adverse drug reactions, as well as reduce the cost of drug development. Pharmacogenomics is a rapidly growing field, with many companies investing in research and development. Examples of companies in the market include 23andMe, Genomics England, and Illumina. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.